瑞舒伐他汀与西他列汀的药物相互作用导致横纹肌溶解症：病例报告。

IF 0.8 Q3 MEDICINE, GENERAL & INTERNAL

Clinical Medicine Insights. Case Reports Pub Date : 2024-09-02 eCollection Date: 2024-01-01 DOI:10.1177/11795476241274162

Abdolamir Atapour, Mahnaz Momenzadeh, Mahsa Panahishokouh, Shirinsadat Badri

{"title":"瑞舒伐他汀与西他列汀的药物相互作用导致横纹肌溶解症：病例报告。","authors":"Abdolamir Atapour, Mahnaz Momenzadeh, Mahsa Panahishokouh, Shirinsadat Badri","doi":"10.1177/11795476241274162","DOIUrl":null,"url":null,"abstract":"Rhabdomyolysis was not reported in clinical trials with Sitagliptin alone. However, several reports in the literature on rhabdomyolysis resulted from the interaction between statins and Sitagliptin. In patients with type 2 diabetes and hyperlipidemia, it is expected to co-prescribe statins and Sitagliptin. Herein, we report the case of a 64-year-old woman with rhabdomyolysis should be caused by a drug-drug interaction between Rosuvastatin and Sitagliptin. The patient denied any history of weakness or myalgia during past medical assessments.","PeriodicalId":10357,"journal":{"name":"Clinical Medicine Insights. Case Reports","volume":"17 ","pages":"11795476241274162"},"PeriodicalIF":0.8000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367606/pdf/","citationCount":"0","resultStr":"{\"title\":\"Rosuvastatin-Induced Rhabdomyolysis as a Result of Drug Interaction With Sitagliptin: A Case Report.\",\"authors\":\"Abdolamir Atapour, Mahnaz Momenzadeh, Mahsa Panahishokouh, Shirinsadat Badri\",\"doi\":\"10.1177/11795476241274162\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rhabdomyolysis was not reported in clinical trials with Sitagliptin alone. However, several reports in the literature on rhabdomyolysis resulted from the interaction between statins and Sitagliptin. In patients with type 2 diabetes and hyperlipidemia, it is expected to co-prescribe statins and Sitagliptin. Herein, we report the case of a 64-year-old woman with rhabdomyolysis should be caused by a drug-drug interaction between Rosuvastatin and Sitagliptin. The patient denied any history of weakness or myalgia during past medical assessments.\",\"PeriodicalId\":10357,\"journal\":{\"name\":\"Clinical Medicine Insights. Case Reports\",\"volume\":\"17 \",\"pages\":\"11795476241274162\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367606/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine Insights. Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/11795476241274162\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795476241274162","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

在单独使用西他列汀的临床试验中没有横纹肌溶解症的报道。然而，文献中有几篇关于横纹肌溶解症的报道是由于他汀类药物和西他列汀之间的相互作用引起的。对于患有 2 型糖尿病和高脂血症的患者，应该同时使用他汀类药物和西他列汀。在此，我们报告了一例 64 岁女性横纹肌溶解症病例，其病因可能是瑞舒伐他汀和西他列汀之间的药物相互作用。患者否认在既往医疗评估中出现过任何虚弱或肌痛病史。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Rosuvastatin-Induced Rhabdomyolysis as a Result of Drug Interaction With Sitagliptin: A Case Report.

Rhabdomyolysis was not reported in clinical trials with Sitagliptin alone. However, several reports in the literature on rhabdomyolysis resulted from the interaction between statins and Sitagliptin. In patients with type 2 diabetes and hyperlipidemia, it is expected to co-prescribe statins and Sitagliptin. Herein, we report the case of a 64-year-old woman with rhabdomyolysis should be caused by a drug-drug interaction between Rosuvastatin and Sitagliptin. The patient denied any history of weakness or myalgia during past medical assessments.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Medicine Insights. Case Reports MEDICINE, GENERAL & INTERNAL-

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

8 weeks